Alzheimer Disease
📧 Sign up to get email alerts when something new happens for Alzheimer Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-03-06Clinical Trial Update: Senolytic Therapy to Modulate Progression of Alzheimer's Disease [Phase 1, Phase 2]
Phase 1/2 clinical trial investigating senolytic therapy to modulate progression of Alzheimer’s disease has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2023-03-02Clinical Trial Update: Transcranial Magnetic Stimulation (TMS) Treatment for Alzheimer Patients [Phase 2]
A Phase 2 clinical trial evaluating transcranial magnetic stimulation (TMS) for Alzheimer disease has completed.
-
CLINICAL_TRIALS trial_result · 2023-03-01Clinical Trial Update: Effect of CT1812 Treatment on Brain Synaptic Density [Phase 1, Phase 2]
Phase 1/2 trial update on CT1812 shows results for Alzheimer's disease; study completed with results posted.
-
CLINICAL_TRIALS trial_result · 2023-02-28Clinical Trial Update: Posiphen® Dose-Finding, Biomarker Study in Early Alzheimer's and Parkinson's Patients [Phase 1, Phase 2]
Phase 1/2 dose-finding biomarker trial of Posiphen in early Alzheimer's and Parkinson's patients completed with results posted.
-
CLINICAL_TRIALS trial_result · 2023-02-23Clinical Trial Update: GAIN Trial: Phase 2/3 Study of COR388 in Subjects With Alzheimer's Disease [Phase 2, Phase 3]
Phase 2/3 study of COR388 (Cortexyme) in Alzheimer's disease completed with results posted in 2023.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-02-22Clinical Trial Update: Clinical Trial to Explore the the Amyloid Beta Draining Effect of Thiethylperazine (TEP) in Subjects With Newly Diagnosed Early-to-mild Dementia Due to Alzheimer's Disease (AD) in Comparison to Healthy Volunteers [Phase 2]
Phase 2 clinical trial evaluating the effect of thiethylperazine (TEP) on amyloid beta drainage in early-to-mild Alzheimer’s disease; study …
-
CLINICAL_TRIALS trial_result · 2023-02-21Clinical Trial Update: Efficacy and Safety of Yangxue Qingnao Pills in the Treatment of Mild to Moderate Alzheimer's Disease [Phase 2]
Phase 2 trial update evaluating the efficacy and safety of Yangxue Qingnao Pills in mild to moderate Alzheimer's disease is in progress, wit…
-
CLINICAL_TRIALS trial_result · 2023-02-16Clinical Trial Update: Effects of THC-Free CBD Oil on Agitation in Patients With Alzheimer's Disease [Phase 2]
Phase 2 clinical trial evaluating effects of THC-free CBD oil on agitation in patients with Alzheimer’s disease and related dementias.
-
CLINICAL_TRIALS trial_result · 2023-02-13Clinical Trial Update: Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type [Phase 3]
Phase 3 trial assessing AVP-786 for agitation in dementia of the Alzheimer's type has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2023-02-09Clinical Trial Update: Protecting Alzheimer Caregivers Using Technology Through Staying Sharp [Phase 1, Phase 2]
A Phase 1/2 clinical trial exploring technology-based interventions to support Alzheimer’s caregivers and address caregiver burden in indivi…
-
CLINICAL_TRIALS trial_result · 2023-02-08Clinical Trial Update: Triglyceride Effects on Blood Flow in the Human Brain [NA]
Clinical trial studying triglyceride effects on blood flow in the human brain for Alzheimer disease has completed; results posted in 2023.
-
CLINICAL_TRIALS trial_result · 2023-02-06Clinical Trial Update: Prazosin for Agitation in Alzheimer's Disease [Phase 2]
Phase 2 clinical trial update for prazosin in agitation associated with Alzheimer's disease has completed with results posted.
-
FDA approval · 2023-02-02FDA Approved: GALANTAMINE — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for galantamine submitted by Aurobindo Pharma Limited.
-
CLINICAL_TRIALS trial_result · 2023-01-26Clinical Trial Update: Study of Low Dose Whole Brain Irradiation in the Treatment of Alzheimer's Disease [NA]
A terminated clinical trial investigated low-dose whole brain irradiation for Alzheimer's disease; results have been posted.
-
FDA approval · 2023-01-18FDA Approved: GALANTAMINE HYDROBROMIDE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for galantamine hydrobromide from Sun Pharmaceutical Industries, Inc., under an ANDA.
-
FDA approval · 2023-01-17FDA Approved: GALANTAMINE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for galantamine from Aurobindo Pharma Limited. This action pertains to a generic product used to tre…
-
CLINICAL_TRIALS trial_result · 2023-01-12Clinical Trial Update: PMZ-1620 (Sovateltide) in Mild to Moderate Alzheimer's Disease [Phase 2]
Phase 2 clinical trial update for PMZ-1620 (Sovateltide) in mild to moderate Alzheimer's disease has completed.
-
FDA approval · 2023-01-06FDA Approved: LEQEMBI — Original Application (Eisai Inc.)
FDA approved LEQEMBI (lecanemab) in an original BLA submission from Eisai Inc. for the treatment of Alzheimer's disease.
-
CLINICAL_TRIALS trial_result · 2022-11-25Clinical Trial Update: Utilizing Senior Companions to Enhance Dementia Care [NA]
A University of Minnesota study evaluated using senior companions to enhance dementia care, and its results were posted after completion in …
-
CLINICAL_TRIALS trial_result · 2022-11-25Clinical Trial Update: Smell, Voice and Nasal Swabs as Markers for Neuro-degenerative Disorders [NA]
Clinical trial update on using smell, voice, and nasal swabs as markers for neuro-degenerative disorders; status completed with results post…
-
CLINICAL_TRIALS trial_result · 2022-11-23Clinical Trial Update: A Study of Sodium Oligomannate (GV-971) in Participants With Mild to Moderate Alzheimer's Disease [Phase 3]
Phase 3 trial of sodium oligomannate (GV-971) in mild to moderate Alzheimer's disease is suspended.
-
CLINICAL_TRIALS trial_result · 2022-11-08Clinical Trial Update: Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease [Phase 2]
A Phase 2 trial of BIIB092 in early Alzheimer's disease was terminated; results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-11-07Clinical Trial Update: Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease [Phase 2]
Phase 2 multiple IV dose study of PF-04360365 in patients with mild to moderate Alzheimer's disease has completed; results posted.
-
CLINICAL_TRIALS trial_result · 2022-10-28Clinical Trial Update: Allogeneic Human Mesenchymal Stem Cells for Alzheimer's Disease [Phase 2]
Phase 2 clinical trial update for allogeneic human mesenchymal stem cells in Alzheimer dementia is ongoing with an unknown status.
-
CLINICAL_TRIALS trial_result · 2022-10-26Clinical Trial Update: The Effects of Intermittent Theta Burst Stimulation in MCI and Early AD [Phase 2]
Phase 2 trial evaluating intermittent theta burst stimulation for mild cognitive impairment and early Alzheimer’s disease has completed.